{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:23:16Z","timestamp":1775150596595,"version":"3.50.1"},"reference-count":59,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Despite the progressive research and recent advances in drug therapy to treat solid tumours, the number of cases and deaths in patients with cancer is still a major health problem. Drug repurposing coupled to drug combination strategies has been gaining interest among the scientific community. Recently, our group proposed novel drug combinations for breast and colon cancer using repurposed drugs from different classes (antimalarial and central nervous system (CNS)) and chemotherapeutic agents such as 5-fluorouracil (5-FU), paclitaxel (PTX), and found promising results. Here, we proposed a novel drug combination using different CNS drugs and doxorubicin (DOX), an antineoplastic used in breast cancer therapy, and studied their anticancer potential in MCF-7 breast cancer cells. Cells were treated with each drug alone and combined with increasing concentrations of DOX and cell viability was evaluated by MTT and SRB assays. Studies were also complemented with morphological evaluation. Assessment of drug interaction was performed using the CompuSyn and SynergyFinder software. We also compiled our previously studied drug pairs and selected the most promising ones for evaluation of the expression of EMT biomarkers (E-cadherin, P-cadherin, vimentin, and \u03b2-catenin) by immunohistochemistry (IHC) to assess if these drug combinations affect the expression of these proteins and eventually revert EMT. These results demonstrate that combination of DOX plus fluoxetine, benztropine, and thioridazine at their IC50 can improve the anticancer effect of DOX but to a lesser degree than when combined with PTX (previous results), resulting in most of the drug interactions being antagonist or additive. This suggests that the choice of the antineoplastic drug influences the success of the drug combination. Collectively, these results also allow us to conclude that antimalarial drugs as repurposed drugs have enhanced effects in MCF-7 breast cancer cells, while combination with CNS drugs seems to be more effective in HT-29 colon cancer cells. The IHC results demonstrate that combination treatments increase E-cadherin expression while reducing P-cadherin, vimentin, and \u03b2-catenin, suggesting that these treatments could induce EMT reversal. Taken together, these results could provide promising approaches to the design of novel drug combinations to treat breast and colon cancer patients.<\/jats:p>","DOI":"10.3390\/biom12020190","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T20:32:52Z","timestamp":1642969972000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-5042","authenticated-orcid":false,"given":"Diana","family":"Duarte","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"given":"Alexandra","family":"R\u00eama","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2305-1631","authenticated-orcid":false,"given":"Irina","family":"Amorim","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal"},{"name":"Institute of Pathology and Molecular Immunology, University of Porto (IPATIMUP), 4200-465 Porto, Portugal"},{"name":"i3S-Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Epithelial-mesenchymal transition in cancer: An overview","volume":"4","author":"Ramos","year":"2017","journal-title":"Integr. Cancer Sci. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-8722-7-19","article-title":"Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions","volume":"7","author":"Guo","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2001-1326-3-17","article-title":"Clinical significance of epithelial-mesenchymal transition","volume":"3","author":"Steinestel","year":"2014","journal-title":"Clin. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1172\/JCI38019","article-title":"Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease","volume":"119","author":"Acloque","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc3447","article-title":"Regulatory networks defining EMT during cancer initiation and progression","volume":"13","author":"Berx","year":"2013","journal-title":"Nat. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1166\/ch.2013.1004","article-title":"Epithelial-Mesenchymal Transition\u2014A Hallmark of Breast Cancer Metastasis","volume":"1","author":"Wang","year":"2013","journal-title":"Cancer Hallm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2217\/fon.09.94","article-title":"Epithelial\u2013mesenchymal transition in development and cancer","volume":"5","author":"Micalizzi","year":"2009","journal-title":"Futur. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1158\/0008-5472.CAN-05-0616","article-title":"Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition?","volume":"65","author":"Thompson","year":"2005","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nrc3603","article-title":"The roles of TGF\u03b2 in the tumour microenvironment","volume":"13","author":"Pickup","year":"2013","journal-title":"Nat. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial\u2013mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-015-0448-4","article-title":"P-cadherin and the journey to cancer metastasis","volume":"14","author":"Vieira","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5732\/cjc.011.10226","article-title":"Epithelial-mesenchymal transition in breast cancer progression and metastasis","volume":"30","author":"Wang","year":"2011","journal-title":"Chin. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/BD-140395","article-title":"Role of PRL-3, Snail, Cytokeratin and Vimentin expression in epithelial mesenchymal transition in breast carcinoma","volume":"35","author":"Patel","year":"2015","journal-title":"Breast Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18632\/oncotarget.756","article-title":"High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion","volume":"4","author":"Lehtinen","year":"2012","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"172784","DOI":"10.1016\/j.ejphar.2019.172784","article-title":"Old wine in new bottles: Drug repurposing in oncology","volume":"866","author":"Antoszczak","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3332\/ecancer.2018.886","article-title":"ReDO_DB: The repurposing drugs in oncology database","volume":"12","author":"Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology\u2014patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","article-title":"Recent advances of cocktail chemotherapy by combination drug delivery systems","volume":"98","author":"Hu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.4103\/0973-1482.235349","article-title":"Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice","volume":"14","author":"Talib","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_22","first-page":"2381","article-title":"Curcumin and paclitaxel induce cell death in breast cancer cell lines","volume":"40","author":"Calaf","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2018.04.035","article-title":"Apoptosis induction in human breast cancer cell lines by synergic effect of raloxifene and resveratrol through increasing proapoptotic genes","volume":"205","author":"Mirzapur","year":"2018","journal-title":"Life Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3892\/ijo.2017.4052","article-title":"Synergistic cytotoxic effects of arsenite and tetrandrine in human breast cancer cell line MCF-7","volume":"51","author":"Yao","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.7314\/APJCP.2012.13.11.5903","article-title":"Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells","volume":"13","author":"Hu","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Duarte, D., Cardoso, A., and Vale, N. (2021). Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147408"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Duarte, D., and Vale, N. (2020). New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells. Biomol., 10.","DOI":"10.3390\/biom10121623"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"127ra36","DOI":"10.1126\/scitranslmed.3003016","article-title":"Anti-Invasive Adjuvant Therapy with Imipramine Blue Enhances Chemotherapeutic Efficacy Against Glioma","volume":"4","author":"Munson","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1158\/1078-0432.CCR-15-2535","article-title":"Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis","volume":"22","author":"Rajamanickam","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/onc.2015.291","article-title":"Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation","volume":"35","author":"Yang","year":"2016","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-04796-1","article-title":"Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells","volume":"7","author":"Metts","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51651","DOI":"10.18632\/oncotarget.10541","article-title":"Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia","volume":"7","author":"Laidlaw","year":"2016","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2017.04.028","article-title":"Aromatase inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and molecular modeling studies of novel phenothiazine derivatives carrying sulfonamide moiety as hybrid molecules","volume":"134","author":"Ghorab","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e1111","DOI":"10.1038\/cddis.2014.56","article-title":"Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer","volume":"5","author":"Zong","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27540","DOI":"10.1038\/srep27540","article-title":"Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents\u2013A drug repurposing strategy","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1535-7163.MCT-16-0169-T","article-title":"Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R","volume":"16","author":"Kang","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.201207-1180OC","article-title":"Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer","volume":"186","author":"Yeh","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/mol.62.2.210","article-title":"The Ca2+Channel Antagonists Mibefradil and Pimozide Inhibit Cell Growth via Different Cytotoxic Mechanisms","volume":"62","author":"Bertolesi","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2011.07.015","article-title":"Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells","volume":"311","author":"Chou","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_41","first-page":"7715","article-title":"Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression","volume":"7","author":"Roca","year":"2015","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/2211-5463.12223","article-title":"Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cells","volume":"7","author":"Liu","year":"2017","journal-title":"FEBS Open Bio"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fphar.2017.00158","article-title":"An Introduction to Terminology and Methodology of Chemical Synergy\u2014Perspectives from Across Disciplines","volume":"8","author":"Roell","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: Visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jcpt.12759","article-title":"Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead","volume":"44","author":"Shah","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","article-title":"Challenges and opportunities with drug repurposing: Finding strategies to find alternative uses of therapeutics","volume":"15","author":"Talevi","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/21691401.2018.1436553","article-title":"Recent progress in synergistic chemotherapy and phototherapy by targeted drug delivery systems for cancer treatment","volume":"46","author":"Cao","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and Dissemination Precede Pancreatic Tumor Formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature14897","article-title":"Distinct EMT programs control normal mammary stem cells and tumour-initiating cells","volume":"525","author":"Ye","year":"2015","journal-title":"Nat."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Morel, A.-P., Li\u00e8vre, M., Thomas, C., Hinkal, G., Ansieau, S., and Puisieux, A. (2008). Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002888"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/ncb3513","article-title":"The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer","volume":"19","author":"Krebs","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4149\/neo_2015_002","article-title":"The contribution of TGF-\u03b2 in Epithelial\u2013Mesenchymal Transition (EMT): Down-regulation of E-cadherin via snail","volume":"62","author":"Yu","year":"2015","journal-title":"Neoplasma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fonc.2014.00371","article-title":"P-Cadherin Linking Breast Cancer Stem Cells and Invasion: A Promising Marker to Identify an \u201cIntermediate\/Metastable\u201d EMT State","volume":"4","author":"Ribeiro","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3904\/kjim.2017.155","article-title":"\u03b2-Catenin expression is associated with cell invasiveness in pancreatic cancer","volume":"34","author":"Nan","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"Satelli","year":"2011","journal-title":"Cell Mol. Life Sci."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/2\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:06:09Z","timestamp":1760133969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/2\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["biom12020190"],"URL":"https:\/\/doi.org\/10.3390\/biom12020190","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,23]]}}}